Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), The Procter ...
Pfizer, facing increasing pressure from Novartis, is touting a Phase III win for Ibrance as the first clinical evidence supporting the CDK4/6 inhibitor class’ use in patients with a specific type of ...
While under competitive pressure from Novartis and Eli Lilly, Pfizer can tally up a unique trial win for its Ibrance in a ...
Although not a game changer for Pfizer, the data could help cushion Ibrance’s losses of market share to Kisqali, a similar ...